About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
IP: Miquel Vila Bover Collaborators: Joan Compte Barrón, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre Funding agency: Michael J. Fox Foundation Funding: 1269495.05 Reference: ASAP_MJFF2021 Duration: 01/11/2021 - 31/10/2024
PMID: 37974302 Journal: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM Year: 2023 Reference: J Cereb Blood Flow Metab. 2023 Nov 16:271678X231214826. doi: 10.1177/0271678X231214826. Impact factor: Publication type: Paper in international publication Authors: Arrue, Mercedes; Buxo, Xavier; Cacho Lavin, Diego; Cano, Juana Maria; Carmona-Bayonas, Alberto; Cerda, Paula; Cruz, Maria-Jesus; Custodio, Ana; de Homdedeu, Miquel; Delgado, Pilar et al. DOI: 10.1177/0271678X231214826
PMID: 37982525 Journal: JOURNAL OF THORACIC IMAGING Year: 2023 Reference: J Thorac Imaging. 2023 Nov 3. doi: 10.1097/RTI.0000000000000758. Impact factor: Publication type: Paper in international publication Authors: Arrue, Mercedes; Buxo, Xavier; Chu, Winnie C; Concepcion, Nathan David P; Cruz, Maria-Jesus; Daltro, Pedro; de Homdedeu, Miquel; Delgado, Pilar; DiPrete, Olivia; Elicegui, Amaia et al. DOI: 10.1097/RTI.0000000000000758
PMID: 37992028 Journal: PLoS One Year: 2023 Reference: PLoS One. 2023 Nov 22;18(11):e0293774. doi: 10.1371/journal.pone.0293774. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Atkova, Irina; Avellanet, Merce; Baldellou, Laura; Chew, Han Shi Jocelyn; Deus, Claudia Maria; Enriquez-Calzada, Silvia; Frondelius, Tuomas; Gea-Rodriguez, Elvira; Gine-Garriga, Maria; Hernandez-Vara, Jorge et al. DOI: 10.1371/journal.pone.0293774
PMID: 37996169 Journal: ANNALS OF ONCOLOGY Year: 2023 Reference: Ann Oncol. 2023 Nov;34(11):962-963. doi: 10.1016/j.annonc.2023.10.002. Impact factor: Publication type: Editorail in international publication Authors: Avellanet, Merce; Baldellou, Laura; Deus, Claudia Maria; Dienstmann, R; Enriquez-Calzada, Silvia; Gea-Rodriguez, Elvira; Gine-Garriga, Maria; Hernandez-Vara, Jorge; Laguna, Ariadna; Magana, Juan Carlos et al. DOI: 10.1016/j.annonc.2023.10.002
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.
This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
